These companies have proven they can rebound from the worst.
News & Analysis: Illumina
The sky is the limit for the leader in DNA sequencing.
The Fools reveal three stock ideas for investors interested in personalized medicine and precision oncology.
We’re pitting off gene sequencing giant Illumina against giant biotech Gilead Sciences to see which company is the better buy for long-term investors.
A system that could revolutionize gene research and a first-in-class cancer therapy could be two of healthcare's biggest advances this year. Plus, UnitedHealth's earnings review, and a preview of Johnson & Johnson's earnings.
Make more profit-friendly decisions by developing a specific and repeatable process for evaluating stocks.